LAWSUIT: DEA Fycompa scheduling delay 'inflicting harm,' Eisai charges
This article was originally published in Scrip
Executive Summary
Fed up with waiting on the slow scheduling pace of the US Drug Enforcement Administration (DEA), Japanese drug maker Eisai has turned to the US Court of Appeals for the District of Columbia hoping legal action will light a fire under the agency to act on the company's epilepsy drug Fycompa (perampanel).